Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
Holders of 5% or more of ESPR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Esperion Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Esperion Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Esperion Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 202511:43 AM ET | Two Seas Capital LPand 2 others | 13G/A | 4.70%9.75M shares | −0.30 ppfrom 5.00%Below 5% | Sep 30, 2025 | SEC |
| Nov 12, 20253:32 PM ET | Wasatch Advisors Inc | 13G/A | 3.50%7.06M shares | −2.00 ppfrom 5.50%Below 5% | Sep 30, 2025 | SEC |
| Aug 13, 20255:47 PM ET | Two Seas Capital LPand 2 others | 13G | 5.00%9.95M shares | New | Jun 30, 2025 | SEC |
| Apr 7, 20252:15 PM ET | Wasatch Advisors Inc | 13G/A | 5.50%10.9M shares | – | Mar 31, 2025 | SEC |
| Mar 10, 202511:12 AM ET | BB Biotech AGand 1 other | 13G/A | 4.90%9.69M shares | −0.10 ppfrom 5.00%Below 5% | Mar 4, 2025 | SEC |
| Feb 14, 20252:37 PM ET | BB Biotech AGand 1 other | 13G/A | 5.00%9.94M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Esperion Therapeutics, Inc. shares.
No Form 144 notices for Esperion Therapeutics, Inc. are on file.